# US 2014/0193511 A1 · Compositions Of Functional Mitochondria And Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193511 A1
- Document ID: US20140193511A1
- Status: Published application
- Kind: A1
- Application number: 14/204,771
- Filed: 2014-03-11
- Published: 2014-07-10
- Earliest claimed: 2011-09-11
- Assignees: Minovia Therapeutics Ltd.
- Applicants: Minovia Therapeutics Ltd.
- Inventors: Natalie Yivgi-Ohana; Uriel Halavee
- Web page: https://patentgrep.com/patent/US20140193511A1

## CPC

- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Mitochondrial compositions and therapeutic methods of using same. Compositions of partially purified functional mitochondria and methods of using the compositions to treat conditions which benefit from increased mitochondrial function by administering the compositions to a subject in need thereof.

## Claims

### Claim 1

A pharmaceutical composition comprising:
a plurality of partially purified functional mitochondria, said functional mitochondria having an intact outer membrane;
wherein the total amount of mitochondrial proteins does not exceed 80% of the total amount of cellular proteins within said composition; and
wherein the composition is devoid of exogenous protease inhibitors.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein said partially purified functional mitochondria are derived from a cell or a tissue selected from the group consisting of: placenta, placental cells grown in culture and blood cells.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, said pharmaceutical composition further comprising a buffer, the buffer being the same type of buffer as an isolation buffer used to isolate said partially purified functional mitochondria.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, said pharmaceutical composition further comprising a saccharide in an amount sufficient to preserve mitochondrial function, the saccharide being the same type of saccharide as that used in an isolation buffer to isolate said partially purified functional mitochondria.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein said saccharide is sucrose.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein said partially purified functional mitochondria are reduced in size by exposure to an ion-exchanger inhibitor.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein said partially purified functional mitochondria have undergone a freeze-thaw cycle.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein said freeze-thaw cycle comprises freezing said partially purified functional mitochondria within a freezing buffer, said freezing buffer comprising a saccharide.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein said saccharide is sucrose.

### Claim 10 (depends on 7)

The pharmaceutical composition of claim 7, wherein said freeze-thaw cycle comprises freezing said partially purified functional mitochondria for at least 24 hours prior to thawing.

### Claim 11

A method of treating a condition which benefits from increased mitochondrial function, said method comprising:
providing a pharmaceutical composition comprising a plurality of partially purified functional mitochondria, said partially purified functional mitochondria having an intact outer membrane, wherein the total amount of mitochondrial proteins does not exceed 80% of the total amount of cellular proteins within said composition, and wherein the composition is devoid of exogenous protease inhibitors; and
administering to a subject in need thereof a therapeutically effective amount of said pharmaceutical composition.

### Claim 12 (depends on 11)

The method of claim 11, wherein said condition which benefits from increased mitochondrial function is a disease or disorder associated with nonfunctional or dysfunctional mitochondria.

### Claim 13 (depends on 11)

The method of claim 11, wherein said partially purified functional mitochondria are derived from a cell or a tissue selected from the group consisting of: placenta, placental cells grown in culture and blood cells.

### Claim 14 (depends on 11)

The method of claim 11, wherein said pharmaceutical composition further comprises a saccharide in an amount sufficient to preserve mitochondrial function, the saccharide being the same type of saccharide as that used in an isolation buffer to isolate said partially purified functional mitochondria.

### Claim 15 (depends on 14)

The method of claim 14, wherein said saccharide is sucrose.

### Claim 16 (depends on 11)

The method of claim 11, wherein said partially purified functional mitochondria are reduced in size by exposure to an ion-exchanger inhibitor.

### Claim 17 (depends on 11)

The method of claim 11, wherein said partially purified functional mitochondria have undergone a freeze-thaw cycle.

### Claim 18 (depends on 17)

The method of claim 17, wherein said freeze-thaw cycle comprises freezing said partially purified functional mitochondria within a freezing buffer, said freezing buffer comprising a saccharide.

### Claim 19 (depends on 18)

The method of claim 18, wherein said saccharide is sucrose.

### Claim 20 (depends on 17)

The method of claim 17, wherein said freeze-thaw cycle comprises freezing said partially purified functional mitochondria for at least 24 hours prior to thawing.